{
  "success": true,
  "pagesUsed": [
    1,
    5,
    6,
    7,
    8,
    10,
    11,
    13,
    14,
    15,
    16,
    17,
    19
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "SYNOPSIS",
        "text": "SYNOPSIS",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "SYNOPSIS",
        "sectionTitle": "SYNOPSIS",
        "sectionType": {
          "id": "96bd8774-6839-4a3b-9a32-70c0897e37ed",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "TIME AND EVENTS SCHEDULE",
        "text": "TIME AND EVENTS SCHEDULE",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "TIME AND EVENTS SCHEDULE",
        "sectionTitle": "TIME AND EVENTS SCHEDULE",
        "sectionType": {
          "id": "e4c8deea-5560-4b34-9416-38d810ff2345",
          "code": "Study Procedures",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Procedures",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_3",
        "name": "ABBREVIATIONS",
        "text": "ABBREVIATIONS",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "ABBREVIATIONS",
        "sectionTitle": "ABBREVIATIONS",
        "sectionType": {
          "id": "18d7df81-4830-46d0-a78d-74180f71fceb",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_4",
        "name": "INTRODUCTION",
        "text": "INTRODUCTION",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "INTRODUCTION",
        "sectionType": {
          "id": "11dec0ae-d177-40b5-a446-d0de007f7441",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4",
          "nci_4_5",
          "nci_4_6",
          "nci_4_7",
          "nci_4_8",
          "nci_4_9"
        ]
      },
      {
        "id": "nc_5",
        "name": "OBJECTIVES AND HYPOTHESES",
        "text": "OBJECTIVES AND HYPOTHESES",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "OBJECTIVES AND HYPOTHESES",
        "sectionType": {
          "id": "ffd39c2a-a1e8-4f06-87b8-302eb25a7024",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2"
        ]
      },
      {
        "id": "nc_6",
        "name": "STUDY DESIGN AND RATIONALE",
        "text": "STUDY DESIGN AND RATIONALE",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "STUDY DESIGN AND RATIONALE",
        "sectionType": {
          "id": "fcdde7b4-72f5-4abd-a9b3-7392bd124336",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_6_1",
          "nci_6_2"
        ]
      },
      {
        "id": "nc_7",
        "name": "STUDY POPULATION",
        "text": "STUDY POPULATION",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "STUDY POPULATION",
        "sectionType": {
          "id": "81869c10-b19d-4a62-95a0-59c6d6678516",
          "code": "Study Population",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Population",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_7_1",
          "nci_7_2",
          "nci_7_3",
          "nci_7_4",
          "nci_7_5"
        ]
      },
      {
        "id": "nc_8",
        "name": "TREATMENT ALLOCATION",
        "text": "TREATMENT ALLOCATION",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "5",
        "sectionTitle": "TREATMENT ALLOCATION",
        "sectionType": {
          "id": "c9dc499d-c35d-4040-b1d2-d0af1cd5a120",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_9",
        "name": "DOSAGE AND ADMINISTRATION",
        "text": "DOSAGE AND ADMINISTRATION",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "6",
        "sectionTitle": "DOSAGE AND ADMINISTRATION",
        "sectionType": {
          "id": "57f3cddf-f518-4cc0-9db7-55067d4d7c0a",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_9_1",
          "nci_9_2",
          "nci_9_3",
          "nci_9_4",
          "nci_9_5"
        ]
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_4_1",
        "name": "Background",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Background"
      },
      {
        "id": "nci_4_2",
        "name": "Nonclinical Studies",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.1",
        "sectionTitle": "Nonclinical Studies"
      },
      {
        "id": "nci_4_3",
        "name": "Clinical Studies",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.2",
        "sectionTitle": "Clinical Studies"
      },
      {
        "id": "nci_4_4",
        "name": "Overview",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.2.1",
        "sectionTitle": "Overview"
      },
      {
        "id": "nci_4_5",
        "name": "Pharmacokinetics",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.2.2",
        "sectionTitle": "Pharmacokinetics"
      },
      {
        "id": "nci_4_6",
        "name": "Pharmacodynamics",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.2.3",
        "sectionTitle": "Pharmacodynamics"
      },
      {
        "id": "nci_4_7",
        "name": "Efficacy",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.2.4",
        "sectionTitle": "Efficacy"
      },
      {
        "id": "nci_4_8",
        "name": "Safety",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.2.5",
        "sectionTitle": "Safety"
      },
      {
        "id": "nci_4_9",
        "name": "Overall Rationale and Goals for the Study",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "Overall Rationale and Goals for the Study"
      },
      {
        "id": "nci_5_1",
        "name": "Objectives",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "Objectives"
      },
      {
        "id": "nci_5_2",
        "name": "Hypotheses",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "Hypotheses"
      },
      {
        "id": "nci_6_1",
        "name": "Overview of Study Design",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Overview of Study Design"
      },
      {
        "id": "nci_6_2",
        "name": "Study Design Rationale",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "Study Design Rationale"
      },
      {
        "id": "nci_7_1",
        "name": "General Considerations",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "General Considerations"
      },
      {
        "id": "nci_7_2",
        "name": "Inclusion Criteria",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.2",
        "sectionTitle": "Inclusion Criteria"
      },
      {
        "id": "nci_7_3",
        "name": "Exclusion Criteria",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3",
        "sectionTitle": "Exclusion Criteria"
      },
      {
        "id": "nci_7_4",
        "name": "Prohibitions and Restrictions",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.4",
        "sectionTitle": "Prohibitions and Restrictions"
      },
      {
        "id": "nci_7_5",
        "name": "Repeat Testing and Subject Rescreening",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.5",
        "sectionTitle": "Repeat Testing and Subject Rescreening"
      },
      {
        "id": "nci_9_1",
        "name": "Study Drugs",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.1",
        "sectionTitle": "Study Drugs"
      },
      {
        "id": "nci_9_2",
        "name": "Concomitant Antihyperglycemic and Other Therapies",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.2",
        "sectionTitle": "Concomitant Antihyperglycemic and Other Therapies"
      },
      {
        "id": "nci_9_3",
        "name": "Management of Glycemic Control",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.2.1",
        "sectionTitle": "Management of Glycemic Control"
      },
      {
        "id": "nci_9_4",
        "name": "Management of Renal and CV Risk Factors",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.2.2",
        "sectionTitle": "Management of Renal and CV Risk Factors"
      },
      {
        "id": "nci_9_5",
        "name": "Management of Medications that May Impact Serum Creatinine Levels",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.2.3",
        "sectionTitle": "Management of Medications that May Impact Serum Creatinine Levels"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "ACEi",
        "expandedText": "angiotensin-converting enzyme inhibitor",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "ADA",
        "expandedText": "American Diabetes Association",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "AEs",
        "expandedText": "adverse events",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "AHA",
        "expandedText": "antihyperglycemic agent",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "ARB",
        "expandedText": "angiotensin receptor blocker",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "CKD",
        "expandedText": "chronic kidney disease",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "CV",
        "expandedText": "cardiovascular",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "DKA",
        "expandedText": "diabetic ketoacidosis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "DRI",
        "expandedText": "direct renin inhibitor",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "eCRF",
        "expandedText": "electronic case report form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "eGFR",
        "expandedText": "estimated glomerular filtration rate",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "EMA",
        "expandedText": "European Medicines Agency",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "ESKD",
        "expandedText": "end-stage kidney disease",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "FDA",
        "expandedText": "Food and Drug Administration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "GTED",
        "expandedText": "Global Trial End Date",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "HbA1c",
        "expandedText": "Glycated Hemoglobin",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "IDMC",
        "expandedText": "independent data monitoring committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "MACE",
        "expandedText": "major adverse cardiac event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "MI",
        "expandedText": "myocardial infarction",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "MRA",
        "expandedText": "mineralocorticoid receptor antagonist",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "mRS",
        "expandedText": "modified Rankin Scale",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "MSRC",
        "expandedText": "Medical Safety Review Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "NSAIDs",
        "expandedText": "non-steroidal anti-inflammatory drugs",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "PCR",
        "expandedText": "urine protein-to-creatinine ratio",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "SAE",
        "expandedText": "serious adverse event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "SGLT2",
        "expandedText": "sodium-glucose co-transporter 2",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "T2DM",
        "expandedText": "type 2 diabetes mellitus",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "UACR",
        "expandedText": "urinary albumin-to-creatinine ratio",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_29",
        "abbreviatedText": "US",
        "expandedText": "United States",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 9,
      "itemCount": 23,
      "abbreviationCount": 29
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Amendment INT-6",
      "versionDate": "06 September 2017",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "ACEi",
          "expansion": "angiotensin-converting enzyme inhibitor"
        },
        {
          "abbreviation": "ADA",
          "expansion": "American Diabetes Association"
        },
        {
          "abbreviation": "AEs",
          "expansion": "adverse events"
        },
        {
          "abbreviation": "AHA",
          "expansion": "antihyperglycemic agent"
        },
        {
          "abbreviation": "ARB",
          "expansion": "angiotensin receptor blocker"
        },
        {
          "abbreviation": "CKD",
          "expansion": "chronic kidney disease"
        },
        {
          "abbreviation": "CV",
          "expansion": "cardiovascular"
        },
        {
          "abbreviation": "DKA",
          "expansion": "diabetic ketoacidosis"
        },
        {
          "abbreviation": "DRI",
          "expansion": "direct renin inhibitor"
        },
        {
          "abbreviation": "eCRF",
          "expansion": "electronic case report form"
        },
        {
          "abbreviation": "eGFR",
          "expansion": "estimated glomerular filtration rate"
        },
        {
          "abbreviation": "EMA",
          "expansion": "European Medicines Agency"
        },
        {
          "abbreviation": "ESKD",
          "expansion": "end-stage kidney disease"
        },
        {
          "abbreviation": "FDA",
          "expansion": "Food and Drug Administration"
        },
        {
          "abbreviation": "GTED",
          "expansion": "Global Trial End Date"
        },
        {
          "abbreviation": "HbA1c",
          "expansion": "Glycated Hemoglobin"
        },
        {
          "abbreviation": "IDMC",
          "expansion": "independent data monitoring committee"
        },
        {
          "abbreviation": "MACE",
          "expansion": "major adverse cardiac event"
        },
        {
          "abbreviation": "MI",
          "expansion": "myocardial infarction"
        },
        {
          "abbreviation": "MRA",
          "expansion": "mineralocorticoid receptor antagonist"
        },
        {
          "abbreviation": "mRS",
          "expansion": "modified Rankin Scale"
        },
        {
          "abbreviation": "MSRC",
          "expansion": "Medical Safety Review Committee"
        },
        {
          "abbreviation": "NSAIDs",
          "expansion": "non-steroidal anti-inflammatory drugs"
        },
        {
          "abbreviation": "PCR",
          "expansion": "urine protein-to-creatinine ratio"
        },
        {
          "abbreviation": "SAE",
          "expansion": "serious adverse event"
        },
        {
          "abbreviation": "SGLT2",
          "expansion": "sodium-glucose co-transporter 2"
        },
        {
          "abbreviation": "T2DM",
          "expansion": "type 2 diabetes mellitus"
        },
        {
          "abbreviation": "UACR",
          "expansion": "urinary albumin-to-creatinine ratio"
        },
        {
          "abbreviation": "US",
          "expansion": "United States"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy",
        "version": "Amendment INT-6",
        "versionDate": "06 September 2017"
      },
      "sections": [
        {
          "number": "SYNOPSIS",
          "title": "SYNOPSIS",
          "type": "Synopsis"
        },
        {
          "number": "TIME AND EVENTS SCHEDULE",
          "title": "TIME AND EVENTS SCHEDULE",
          "type": "Study Procedures"
        },
        {
          "number": "ABBREVIATIONS",
          "title": "ABBREVIATIONS",
          "type": "Other"
        },
        {
          "number": "1",
          "title": "INTRODUCTION",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "Background"
            },
            {
              "number": "1.1.1",
              "title": "Nonclinical Studies"
            },
            {
              "number": "1.1.2",
              "title": "Clinical Studies"
            },
            {
              "number": "1.1.2.1",
              "title": "Overview"
            },
            {
              "number": "1.1.2.2",
              "title": "Pharmacokinetics"
            },
            {
              "number": "1.1.2.3",
              "title": "Pharmacodynamics"
            },
            {
              "number": "1.1.2.4",
              "title": "Efficacy"
            },
            {
              "number": "1.1.2.5",
              "title": "Safety"
            },
            {
              "number": "1.2",
              "title": "Overall Rationale and Goals for the Study"
            }
          ]
        },
        {
          "number": "2",
          "title": "OBJECTIVES AND HYPOTHESES",
          "type": "Objectives",
          "subsections": [
            {
              "number": "2.1",
              "title": "Objectives"
            },
            {
              "number": "2.2",
              "title": "Hypotheses"
            }
          ]
        },
        {
          "number": "3",
          "title": "STUDY DESIGN AND RATIONALE",
          "type": "Study Design",
          "subsections": [
            {
              "number": "3.1",
              "title": "Overview of Study Design"
            },
            {
              "number": "3.2",
              "title": "Study Design Rationale"
            }
          ]
        },
        {
          "number": "4",
          "title": "STUDY POPULATION",
          "type": "Study Population",
          "subsections": [
            {
              "number": "4.1",
              "title": "General Considerations"
            },
            {
              "number": "4.2",
              "title": "Inclusion Criteria"
            },
            {
              "number": "4.3",
              "title": "Exclusion Criteria"
            },
            {
              "number": "4.4",
              "title": "Prohibitions and Restrictions"
            },
            {
              "number": "4.5",
              "title": "Repeat Testing and Subject Rescreening"
            }
          ]
        },
        {
          "number": "5",
          "title": "TREATMENT ALLOCATION",
          "type": "Treatment"
        },
        {
          "number": "6",
          "title": "DOSAGE AND ADMINISTRATION",
          "type": "Treatment",
          "subsections": [
            {
              "number": "6.1",
              "title": "Study Drugs"
            },
            {
              "number": "6.2",
              "title": "Concomitant Antihyperglycemic and Other Therapies"
            },
            {
              "number": "6.2.1",
              "title": "Management of Glycemic Control"
            },
            {
              "number": "6.2.2",
              "title": "Management of Renal and CV Risk Factors"
            },
            {
              "number": "6.2.3",
              "title": "Management of Medications that May Impact Serum Creatinine Levels"
            }
          ]
        }
      ]
    }
  }
}